Answers are grounded in this paper and cite their sources.
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lympho-proliferative malignancies with variable patterns of behavior and response to treatments. Although many patients respond to conventional therapies, many relapse and become refractory to further treatments. Studies using B-NHL cell lines have shown that the Yin Yang 1 (YY1) transcription factor is implicated in the regulation of resistance to both chemotherapeutic and immunotherapeutic drugs. This study examined the involvement of YY1 in the spectrum of B-cell neoplasia. The transcript levels of YY1 were evaluated using two different data sets of publicly available microarrays for lymphoma tumor biopsy specimens. The findings revealed that YY1 expression levels increased in association with B-cell transformation, suggesting that YY1 may be involved in B-cell transformation and may give rise to Burkitt's lymphoma and diffuse large B-cell lymphoma.
No takes yet. Share an insight, caveat, or question.
Libra et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: